You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Non-Hodgkins Lymphoma (NHL),RIXIMYO (rituximab) is indicated for treatment of patients with:, CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,, CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.,Chronic Lymphocytic Leukaemia (CLL),RIXIMYO (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,Rheumatoid Arthritis (RA),RIXIMYO (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,Granulomatosis with polyangiitis (Wegeners) (GPA) and Microscopic polyangiitis (MPA),RIXIMYO (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with rituximab have not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Non-Hodgkins Lymphoma (NHL),RIXIMYO (rituximab) is indicated for treatment of patients with:, CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,, CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.,Chronic Lymphocytic Leukaemia (CLL),RIXIMYO (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,Rheumatoid Arthritis (RA),RIXIMYO (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,Granulomatosis with polyangiitis (Wegeners) (GPA) and Microscopic polyangiitis (MPA),RIXIMYO (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with rituximab have not been established.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Non-Hodgkins Lymphoma (NHL),RIXIMYO (rituximab) is indicated for treatment of patients with:, CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,, CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.,Chronic Lymphocytic Leukaemia (CLL),RIXIMYO (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,Rheumatoid Arthritis (RA),RIXIMYO (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,Granulomatosis with polyangiitis (Wegeners) (GPA) and Microscopic polyangiitis (MPA),RIXIMYO (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with rituximab have not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Non-Hodgkins Lymphoma (NHL),RIXIMYO (rituximab) is indicated for treatment of patients with:, CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,, CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.,Chronic Lymphocytic Leukaemia (CLL),RIXIMYO (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,Rheumatoid Arthritis (RA),RIXIMYO (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,Granulomatosis with polyangiitis (Wegeners) (GPA) and Microscopic polyangiitis (MPA),RIXIMYO (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with rituximab have not been established.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
